In a report released today, Ritu Baral from Cowen & Co. maintained a Buy rating on Aptinyx (APTX). The company’s shares closed last Monday at $3.40, close to its 52-week low of $2.61.
According to TipRanks.com, Baral is a 5-star analyst with an average return of 18.2% and a 45.3% success rate. Baral covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Madrigal Pharmaceuticals, and ACADIA Pharmaceuticals.
Currently, the analyst consensus on Aptinyx is a Moderate Buy with an average price target of $7.00.
See today’s analyst top recommended stocks >>
The company has a one-year high of $26.74 and a one-year low of $2.61. Currently, Aptinyx has an average volume of 107.3K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Aptinyx Inc. is a clinical stage biopharmaceutical company. It engages in the discovery, development, and and commercialization of transformative therapies for disorders of the brain and nervous system. Its product includes NYX-2925, NYX-783, NYX-458, and the AGN-241751 program.
